连接桥粒斑珠蛋白促进高级别浆液性卵巢癌恶性进展的机制

doi:10.3969/j.issn.1006-5725.2025.24.008

Abstract

Abstract:

Objective To investigate the role of junction plakoglobin （JUP） in high-grade serous ovarian cancer （HGSOC） and its influence on SET domain bifurcated 1 （SETDB1）. Methods Human HGSOC cell lines with stable JUP overexpression or knockdown were established. The impact of JUP on cell proliferation， invasion， and migration was evaluated in vitro using colony formation， Transwell invasion， and wound healing assays. A subcutaneous xenograft model in nude mice was generated to dynamically monitor tumor growth and peritoneal nodule development， thereby elucidating the role of JUP in tumoral proliferation and metastasis. Co-immunoprecipitation （Co-IP） assays were performed to identify downstream molecules regulated by JUP. RT-qPCR， Western blotting， and histone methyltransferase activity assays were utilized to validate the influence of JUP on SETDB1 expression and enzymatic activity. Furthermore， rescue experiments were conducted to assess whether reconstitution of SETDB1 could reverse the malignant phenotypes induced by JUP knockdown in HGSOC cells. Results JUP was significantly overexpressed in high-grade serous ovarian cancer （HGSOC） tissues （P < 0.000 1）， and patients with elevated JUP expression exhibited a poorer prognosis （P < 0.05）. In vitro experiments demonstrated that JUP overexpression enhanced tumor cell proliferation， invasion， and migration， whereas JUP knockdown suppressed these malignant phenotypes （P < 0.01）. In vivo studies further confirmed that JUP promoted tumor growth and peritoneal metastasis. Mechanistic analyses revealed that JUP directly interacts with SETDB1 and enhances its methyltransferase activity； notably， the oncogenic effects induced by JUP overexpression were reversed upon SETDB1 knockdown （P < 0.05）. Conclusion JUP promotes the malignant progression of HGSOC by directly binding to and modulating the enzymatic activity of SETDB1， highlighting its potential as a therapeutic target for HGSOC.

Key words: high-grade serous ovarian cancer, JUP, SETDB1, proliferation, metastasis

CLC Number:

R737.31

Yutang HUANG,Weiqin DU,Dong YUAN,Tiantian LEI,Chunjie WEN,Lanxiang. WU. The mechanism of JUP promoting the malignant progression of high⁃grade serous ovarian cancer[J]. The Journal of Practical Medicine, 2025, 41(24): 3848-3859.

Figures/Tables 8

Tab.1

Fig. 1

Tab.2

Tab. 3

Fig.2

Fig. 3

Fig.4

Fig.5

References 32

[1]	SIEGEL R L， KRATZER T B， GIAQUINTO A N， et al. Cancer statistics， 2025［J］. CA Cancer J Clin， 2025， 75（1）： 10-45. doi:10.3322/caac.21871 doi: 10.3322/caac.21871
[2]	CARUSO G， WEROHA S J， CLIBY W. Ovarian Cancer： A Review［J］. JAMA， 2025， 334（14）： 1278-1291. doi:10.1001/jama.2025.9495 doi: 10.1001/jama.2025.9495
[3]	SANTORO A， ANGELICO G， TRAVAGLINO A， et al. The multiple facets of ovarian high grade serous carcinoma： A review on morphological， immunohistochemical and molecular features［J］. Crit Rev Oncol Hematol， 2025， 208： 104603. doi:10.1016/j.critrevonc.2024.104603 doi: 10.1016/j.critrevonc.2024.104603
[4]	DENG M， YANG R， JIANG J， et al. The silent spread： Exploring diverse metastatic pathways in high-grade serous ovarian cancer［J］. Front Med （Lausanne）， 2025， 12： 1539024. doi:10.3389/fmed.2025.1539024 doi: 10.3389/fmed.2025.1539024
[5]	FU R， HU R， LI W， et al. Unveiling drug resistance pathways in high-grade serous ovarian cancer （HGSOC）： Recent advances and future perspectives［J］. Front Immunol， 2025， 16： 1556377. doi:10.3389/fimmu.2025.1556377 doi: 10.3389/fimmu.2025.1556377
[6]	KORDOWITZKI P， LANGE B， ELIAS K M， et al. Transforming treatment paradigms： Focus on personalized medicine for high-grade serous ovarian cancer［J］. CA Cancer J Clin， 2025， 75（5）： 436-460. doi:10.3322/caac.70008 doi: 10.3322/caac.70008
[7]	GAILLARD S， LACCHETTI C， ARMSTRONG D K， et al. Neoadjuvant Chemotherapy for Newly Diagnosed， Advanced Ovarian Cancer： ASCO Guideline Update［J］. J Clin Oncol， 2025， 43（7）： 868-891. doi:10.1200/op-24-00999 doi: 10.1200/op-24-00999
[8]	POLAJZER S， CERNE K. Precision Medicine in High-Grade Serous Ovarian Cancer： Targeted Therapies and the Challenge of Chemoresistance［J］. Int J Mol Sci， 2025， 26（6）： 2545. doi:10.3390/ijms26062545 doi: 10.3390/ijms26062545
[9]	DIAS M P， MOSER S C， GANESAN S， et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy［J］. Nat Rev Clin Oncol， 2021， 18（12）： 773-791. doi:10.1038/s41571-021-00532-x doi: 10.1038/s41571-021-00532-x
[10]	GUPTA R， KUMAR R， PENN C A， et al. Immune evasion in ovarian cancer： Implications for immunotherapy and emerging treatments［J］. Trends Immunol， 2025， 46（2）： 166-181. doi:10.1016/j.it.2024.12.006 doi: 10.1016/j.it.2024.12.006
[11]	WANG J， DEAN D C， HORNICEK F J， et al. RNA sequencing （RNA-Seq） and its application in ovarian cancer［J］. Gynecol Oncol， 2019， 152（1）： 194-201. doi:10.1016/j.ygyno.2018.10.002 doi: 10.1016/j.ygyno.2018.10.002
[12]	何婉珊，洪小山，陈冠桥，等. 基于转录组测序技术筛选NSUN2在卵巢癌细胞的基因差异表达［J］. 实用医学杂志， 2023， 39（9）： 1079-1085.
[13]	LI J， SWOPE D， RAESS N， et al. Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of beta-catenin signaling［J］. Mol Cell Biol， 2011， 31（6）： 1134-1144. doi:10.1128/mcb.01025-10 doi: 10.1128/mcb.01025-10
[14]	DING W， SUN J， SONG S， et al. Junction Plakoglobin - A Dual-Role Player in Cancer Biology［J］. Int J Surg， 2025， 111（6）： 3920-3930. doi:10.1097/js9.0000000000002365 doi: 10.1097/js9.0000000000002365
[15]	CHEN K， ZENG J， SUN Y， et al. Junction plakoglobin regulates and destabilizes HIF2alpha to inhibit tumorigenesis of renal cell carcinoma［J］. Cancer Commun （Lond）， 2021， 41（4）： 316-332. doi:10.1002/cac2.12142 doi: 10.1002/cac2.12142
[16]	WANG Z， HU J， CHEN J， et al. ICAT promotes colorectal cancer metastasis via binding to JUP and activating the NF-kappaB signaling pathway［J］. J Clin Lab Anal， 2022， 36（10）： e24678. doi:10.1002/jcla.24678 doi: 10.1002/jcla.24678
[17]	LHEUREUX S， GOURLEY C， VERGOTE I， et al. Epithelial ovarian cancer［J］. Lancet， 2019， 393（10177）： 1240-1253. doi:10.1016/s0140-6736(18)32552-2 doi: 10.1016/s0140-6736(18)32552-2
[18]	LIU J F， KONSTANTINOPOULOS P A， MATULONIS U A. PARP inhibitors in ovarian cancer： Current status and future promise［J］. Gynecol Oncol， 2014， 133（2）： 362-369. doi:10.1016/j.ygyno.2014.02.039 doi: 10.1016/j.ygyno.2014.02.039
[19]	黄山高，吴月玲，张颖. 瞄准未来：卵巢癌靶向治疗的新进展［J］. 实用医学杂志， 2024， 40（14）： 1901-1907.
[20]	DENG X， SHEN A， JIANG L. Bioinformatics analysis of JUP in patients with acute myocardial infarction and its potential application in clinical prognostic evaluation［J］. Front Cardiovasc Med， 2025， 12： 1531309. doi:10.3389/fcvm.2025.1531309 doi: 10.3389/fcvm.2025.1531309
[21]	VAHIDNEZHAD H， YOUSSEFIAN L， FAGHANKHANI M， et al. Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility［J］. Sci Rep， 2020， 10（1）： 21622. doi:10.1038/s41598-020-78344-9 doi: 10.1038/s41598-020-78344-9
[22]	YANG L， HUANG W， BAI X， et al. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling［J］. Cell Death Dis， 2023， 14（6）： 363. doi:10.1038/s41419-023-05882-1 doi: 10.1038/s41419-023-05882-1
[23]	XIA J， MA N， SHI Q， et al. XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis［J］. J Cell Biol， 2024， 223（2）： e202303015. doi:10.1083/jcb.202303015 doi: 10.1083/jcb.202303015
[24]	CHEN Y， YANG L， QIN Y， et al. Effects of differential distributed-JUP on the malignancy of gastric cancer［J］. J Adv Res， 2021， 28： 195-208. doi:10.1016/j.jare.2020.06.026 doi: 10.1016/j.jare.2020.06.026
[25]	HU J， HUANG R， LIANG C， et al. TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP［J］. Mol Cancer Res， 2023， 21（10）： 1107-1119. doi:10.1158/1541-7786.mcr-23-0113 doi: 10.1158/1541-7786.mcr-23-0113
[26]	KANG Y K. SETDB1 in Early Embryos and Embryonic Stem Cells［J］. Curr Issues Mol Biol， 2015， 17： 1-10. doi:10.21775/cimb.017.001 doi: 10.21775/cimb.017.001
[27]	MARKOULI M， STREPKOS D， PIPERI C. Structure， Activity and Function of the SETDB1 Protein Methyltransferase［J］. Life （Basel）， 2021， 11（8）： 817. doi:10.3390/life11080817 doi: 10.3390/life11080817
[28]	LUO H， WU X， ZHU X H， et al. The functions of SET domain bifurcated histone lysine methyltransferase 1 （SETDB1） in biological process and disease［J］. Epigenetics Chromatin， 2023， 16（1）： 47. doi:10.1186/s13072-023-00519-1 doi: 10.1186/s13072-023-00519-1
[29]	LAZARO-CAMP V J， SALARI K， MENG X， et al. SETDB1 in cancer： Overexpression and its therapeutic implications［J］. Am J Cancer Res， 2021， 11（5）： 1803-1827.
[30]	WANG W， WANG J， ZHANG X， et al. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer［J］. Onco Targets Ther， 2019， 12： 7451-7457. doi:10.2147/ott.s220700 doi: 10.2147/ott.s220700
[31]	YANG H， SUI L， CAI C， et al. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer［J］. J Ovarian Res， 2024， 17（1）： 34. doi:10.1186/s13048-024-01358-8 doi: 10.1186/s13048-024-01358-8
[32]	STREPKOS D， MARKOULI M， KLONOU A， et al. Histone Methyltransferase SETDB1： A Common Denominator of Tumorigenesis with Therapeutic Potential［J］. Cancer Res， 2021， 81（3）： 525-534. doi:10.1158/0008-5472.can-20-2906 doi: 10.1158/0008-5472.can-20-2906

影响因素	总生存期/d	χ2值	P值
年龄		3.652	0.056
< 56岁（n = 27）	52.037
≥ 56岁（n = 25）	78.080
FIGO分期		5.707	0.0169
Ⅰ+Ⅱ（n = 19）	83.263
Ⅲ+Ⅳ（n = 33）	53.788
淋巴结转移		4.193	0.0406
阳性（n = 32）	54.250
阴性（n = 20）	81.050
大网膜转移		4.786	0.0287
阳性（n = 28）	52.464
阴性（n = 24）	78.667
JUP表达量		7.325	0.0068
高表达（n = 41）	57.341
低表达（n = 11）	91.454

项目	JUP低表达	JUP高表达	χ2值	P值
年龄			0.767	0.3812
< 56岁	7（13.5）	20（38.5）
≥ 56岁	4（7.7）	21（40.4）
FIGO分期			1.951	0.1625
Ⅰ+Ⅱ	6（11.5）	13（25.0）
Ⅲ+Ⅳ	5（9.6）	28（53.8）
淋巴结转移			11.080	0.0009
阳性	2（3.8）	30（57.7）
阴性	9（17.3）	11（21.2）
大网膜转移			3.964	0.0465
阳性	3（5.8）	25（48.1）
阴性	8（15.4）	16（30.8）

The mechanism of JUP promoting the malignant progression of high⁃grade serous ovarian cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 8

References 32

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yin GUO,Haiqing REN,Xiaoyang GUO,Jianghua ZUO,Ting. WANG. Study on the correlation between serum APRIL， PLA2R⁃Ab， and 25⁃（OH） D₃ levels and the severity and prognosis of primary membranous nephropathy [J]. The Journal of Practical Medicine, 2025, 41(8): 1199-1204.
[2]	Likun WANG,Qi HAO,Weihan JIN,Shizheng DONG,Xueliang WU,Xiaofeng HU,Liang WU,Jing XUN,Hongqing MA. Application of multi⁃omics and artificial intelligence in the prediction and diagnosis of liver metastases in colorectal cancer [J]. The Journal of Practical Medicine, 2025, 41(7): 1070-1078.
[3]	Meiyu GAN,Chunjiao WU,Jingyi QIN,Zuojie. LUO. The effect of vanadyl bis（acetylacetonato） on the proliferation and invasion of human adrenocortical carcinoma cells [J]. The Journal of Practical Medicine, 2025, 41(6): 781-789.
[4]	Hongyan BIAN,Shu ZHANG,Shanshan MENG,Ying WEI. Effect of pomegranate peel polyphenols on the malignant biological behavior of colon cancer cells by regulating the miR⁃138⁃5p/HIF⁃1α pathway [J]. The Journal of Practical Medicine, 2025, 41(5): 676-682.
[5]	Changhui WU,Zhiping HUANG,Huiping DAI,Huifang QIU,Chun HE,Fang. TANG. Energy efficiency of contrast⁃enhanced ultrasound combined with TERT promoter mutation to construct a nomogram model for the prediction of concomitant cervical lymph node metastasis in PTMC [J]. The Journal of Practical Medicine, 2025, 41(5): 756-765.
[6]	Yi WEI,Chunhui RAO,Huize LIU,Wen. CHEN. Predictive value of multimodal nomogram on the risk of metastasis and recurrence in patients with stage Ⅱ colorectal cancer without adjuvant treatment [J]. The Journal of Practical Medicine, 2025, 41(23): 3723-3729.
[7]	Jixin CHAI,Yong CHEN,Xue ZHANG,Yazhou AO,Bo. LI. Clinical application of combined clinical pathological features and genetic testing in predicting occult lymph node metastasis in patients with papillary thyroid microcarcinoma [J]. The Journal of Practical Medicine, 2025, 41(22): 3572-3578.
[8]	Dongmei FANG,Yuanyuan QI,Chunjing CAO,Fang WANG,Mingze. LI. Clinical significance of circular RNA circ-PHC3 expression in cervical cancer tissues and its effects on the proliferation， migration and invasion of cervical cancer cells [J]. The Journal of Practical Medicine, 2025, 41(20): 3145-3154.
[9]	Wei YANG,Xiahai LIANG,Huidong XIA,Ru. BAI. The expression of TUBB2A in HCC and its effect on malignant biological behaviors of HCC cells under hypoxia [J]. The Journal of Practical Medicine, 2025, 41(20): 3175-3184.
[10]	Xiaoying DING,Zhichao DONG,Jianna MAO,Changqing GUO,Aimin. YUE. Expression and clinical significance of serum CXCL1 and PRDM5 in lymph node metastasis of progressive gastric cancer [J]. The Journal of Practical Medicine, 2025, 41(20): 3206-3213.
[11]	Jinlan GUO,Xiaoning ZHANG,Jiahui JIANG,Tao. YUAN. Expression of ACTN1 in cutaneous squamous cell carcinoma and its correlation with clinicopathological features and prognosis [J]. The Journal of Practical Medicine, 2025, 41(2): 232-237.
[12]	Peijing DU,Enxi HU,Xiang TAO,Jia CAO,Libin WANG. Super⁃enhancer⁃mediated GSE1 activation drives breast cancer proliferation through Wnt/β⁃catenin signaling [J]. The Journal of Practical Medicine, 2025, 41(18): 2796-2805.
[13]	Shanshan YAN,Huiyu ZHANG,Jun GU,Kan ZHANG,Yu ZHAO. Value of preoperative ultrasound combined with NLR， Ctn and CEA levels in predicting cervical lymph node metastasis of papillary thyroid carcinoma [J]. The Journal of Practical Medicine, 2025, 41(18): 2859-2864.
[14]	Mengying ZHANG,Yaokai MA,Yifan DU,Wei ZHANG,Bo ZHOU,Xiyi YANG. A Randomized controlled study on the efficacy of HAIC sequential DEB⁃TACE in the treatment of colorectal cancer liver metastasis [J]. The Journal of Practical Medicine, 2025, 41(17): 2721-2728.
[15]	Zelin XU,Zhenhao ZHENG,Yaqian DENG,Guanming ZENG,Tingting DU,Peishan ZHU,Wen LIU,Jun. LI. Predictive value of dual‑modality ultrasound combined with S‑Detect for cervical lymph node metastasis in papillary thyroid carcinoma [J]. The Journal of Practical Medicine, 2025, 41(16): 2581-2589.